Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients - 09/08/11
, Yvonne Sun, MD a, Jennifer K. Tan, BA a, Andrew Wang, AB a, Melissa Magliocco, MD a, Melissa Yao, BA a, James G. Krueger, MD, PhD b, Alice B. Gottlieb, MD, PhD c
Reprint requests: Rama Malaviya, PhD, Division of Clinical Pharmacology, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, 1 Robert Wood Johnson Pl, New Brunswick, NJ 08903-0019.New Brunswick, New Jersey; New York, New York; and Boston, Massachusetts
Abstract |
Background |
Etanercept is a tumor necrosis factor-⍺ binding fusion protein that demonstrates efficacy in the treatment of psoriasis, which is accompanied by decreased plaque infiltration of T cells and myeloid dendritic cells. We hypothesized that etanercept decreases inflammatory cell infiltration by inducing apoptosis.
Objective |
We sought to investigate the effect of etanercept on circulating and plaque leukocyte apoptosis in psoriasis.
Methods |
Blood and plaque specimens were obtained from 10 patients with psoriasis treated with etanercept (25 mg subcutaneously twice weekly) for 24 weeks. Apoptosis was determined in tissue samples using immunohistochemistry and flow cytometry.
Results |
Etanercept selectively induced apoptosis in dermal dendritic cells in plaques of responding patients at 1 month, before most of the clinical and histologic response was achieved. No apoptosis was detected in plaque or circulating T cells or in circulating monocytes.
Limitations |
Addition of multiple time points earlier than 1 month would be valuable to establish the time point of maximum induction in cell apoptosis.
Conclusion |
Etanercept selectively induces apoptosis of pathogenic dermal dendritic cells in responding patients early in the course of treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations used : DC, FITC, IL, NF, PASI, PBMC, TNF
Plan
| Supported in part by an investigator-initiated study (Dr Gottlieb) funded by Amgen, by general support to the Psoriasis Center of Excellence by Beiersdorf (to Dr Gottlieb), and by a grant from the David Ju Foundation (to Dr Gottlieb). Disclosure: Dr Gottlieb is an investigator, consultant, and speaker for Amgen and Wyeth, and a consultant and investigator for Centocor and Abbott. Dr Krueger receives research funding from Amgen. Dr Magliocco had received a fellowship from Amgen in the past. |
Vol 55 - N° 4
P. 590-597 - octobre 2006 Retour au numéro
Article précédent
- What’s new online?
- Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
- Kenneth B. Gordon, Richard G. Langley, Craig Leonardi, Darryl Toth, M. Alan Menter, Sewon Kang, Michael Heffernan, Bruce Miller, Regina Hamlin, Liberata Lim, Jianhua Zhong, Rebecca Hoffman, Martin M. Okun
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?